Does SAMe help when antidepressants don’t work?
Yes, in one small trial. Adding SAMe roughly doubled response rates (36.1% vs. 17.6%) and more than doubled remission rates (25.8% vs. 11.7%) compared to placebo. About 1 in 6 patients responded who would not have on placebo. The randomized trial enrolled 73 patients whose depression had not responded to a serotonin reuptake inhibitor (SRI), and the authors call the results preliminary.
SAMe is a naturally occurring methyl donor in the one-carbon cycle. It is thought to support the making of brain neurotransmitters like serotonin, dopamine, and norepinephrine.
What the data show:
- Response rates: 36.1% with SAMe vs. 17.6% with placebo (approximately 2 times greater)
- Remission rates: 25.8% with SAMe vs. 11.7% with placebo (more than 2 times greater)
- Study scope: Randomized controlled trial of 73 SRI nonresponders with major depression over 6 weeks
- Tolerability: Well-tolerated, with no significant difference in dropouts due to side effects (5.1% vs. 8.8%)
A randomized, double-blind clinical trial published in the American Journal of Psychiatry, with an accompanying editorial, suggests that SAMe can help patients with major depressive disorder who have not responded to an SRI. The authors say the results need replication.
Dr. Kumar’s Take
This study matters because SAMe is a different kind of add-on than aripiprazole or quetiapine, the usual augmentation drugs, which carry metabolic side effects. The response rates (36.1% vs 17.6% for placebo) and remission rates (25.8% vs 11.7%) are clinically meaningful, though this trial compared SAMe only with placebo, not with those drugs. SAMe is a naturally occurring molecule that serves as a methyl donor in the body’s cells. For patients who haven’t responded to an SRI, SAMe looks like a well-tolerated option worth confirming in larger trials.
Study Snapshot
This randomized, placebo-controlled trial investigated SAMe augmentation in 73 patients with major depression who had not responded to an SRI. Participants were randomly assigned to receive either SAMe (targeted dose of 800 mg twice daily) or placebo, both added to their ongoing antidepressant regimen for 6 weeks. The primary outcome was the response rate on the 17-item Hamilton Depression Rating Scale (HDRS).
Results in Real Numbers
The randomized, double-blind clinical trial enrolled 73 patients with major depressive disorder who had not responded to a serotonin reuptake inhibitor (SRI). Participants were randomly assigned to receive either SAMe (target dose 800 mg twice daily, totaling 1,600 mg/day) or placebo, both added to their unchanged antidepressant dose for 6 weeks. The primary outcome was the response rate on the Hamilton Depression Rating Scale (HDRS).
SAMe augmentation produced approximately 2 times greater response rates compared to placebo: 36.1% of patients achieved response with SAMe versus 17.6% with placebo. Remission rates were also more than 2 times greater with SAMe: 25.8% achieved remission versus 11.7% with placebo. The number needed to treat was about 6 for response and about 7 for remission. In other words, about 1 in 6 patients responded to SAMe who would not have responded to placebo.
SAMe was well-tolerated throughout the trial, with no significant difference in dropouts for any reason (20.6% vs. 29.5%), due to side effects (5.1% vs. 8.8%), or due to lack of benefit (5.1% vs. 11.7%). The authors call the results preliminary and say they need to be replicated.
Who Benefits Most
Patients with major depressive disorder who have not responded adequately to an SRI are the group this trial studied. They stayed on their SRI at a stable dose and added either SAMe or placebo.
Because the trial compared SAMe only with placebo, it cannot say whether SAMe is a better choice than aripiprazole, quetiapine, or other add-on drugs for any particular person. The authors call the results preliminary and say they need replication.
Safety, Limits, and Caveats
While SAMe was well-tolerated in this study, it can cause side effects including gastrointestinal upset, anxiety, or insomnia in some individuals. The compound requires careful dosing and monitoring when used as augmentation therapy with antidepressants.
Quality and bioavailability of SAMe products vary significantly, making it crucial to use pharmaceutical-grade preparations. SAMe is also more expensive than many other supplements, which may limit accessibility for some patients requiring long-term treatment.
Practical Takeaways
- Consider discussing SAMe augmentation with healthcare providers if you’ve had inadequate response to SSRI treatment
- Understand that SAMe has not been tested head to head against FDA-approved augmentation medications
- Choose pharmaceutical-grade SAMe products to ensure proper dosing and bioavailability
- Work with healthcare providers to properly integrate SAMe into existing treatment regimens
What This Means for Depression Treatment
This study supports SAMe as a promising augmentation strategy for depression that has not responded to an SRI, offering a possible alternative to conventional psychiatric augmentation medications. Because it was a small, 6-week trial, the findings need replication before SAMe can be considered a standard option.
Related Studies and Research
- Episode 31: Depression Explained, The Biology Behind the Darkness
- Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
- Treatment-Resistant Depression: STAR-D Trial Insights
FAQs
How does SAMe compare to FDA-approved augmentation medications?
This trial compared SAMe only with placebo, so it cannot show how SAMe stacks up against aripiprazole or quetiapine. SAMe is a different kind of compound, a naturally occurring methyl donor, and a head-to-head trial would be needed to compare them.
What dose of SAMe was used in this study?
The study used a target dose of 800 mg twice daily (1600 mg total daily dose) added to ongoing antidepressant treatment.
Is SAMe safe to combine with SSRIs?
In this 6-week trial, SAMe added to ongoing SRI treatment was well tolerated, but medical supervision is recommended for proper monitoring and dosing.
Bottom Line
In one small trial, adding SAMe roughly doubled response and remission rates for patients with major depressive disorder who had not responded to an SRI, and it was well tolerated. Larger trials are needed to confirm it.
